Atrion Reports Second Quarter Results

Rhea-AI Summary

Atrion Corporation (NASDAQ: ATRI) reported second-quarter revenues of $42.7 million, up from $38.0 million in Q2 2020. Net income rose to $8.9 million compared to $8.6 million year-over-year, with diluted earnings per share at $4.88, up from $4.68. The company noted a 9% increase in revenues and a 10% increase in operating income sequentially. Looking ahead, Atrion expects approximately a 25% increase in sales and operating income for the remainder of 2021, barring COVID-19 disruptions. Cash and investments totaled $80.0 million as of June 30, 2021.

Positive

• Q2 2021 revenues increased by 12% year-over-year.
• Net income rose to $8.9 million, a 3.5% increase from Q2 2020.
• Diluted earnings per share increased to $4.88 from $4.68 in the previous year.
• Sequential growth: 9% in revenues and 10% in operating income.
• Projected 25% increase in sales and operating income for the rest of 2021.
• Strong cash position with $80 million in short and long-term investments.

Negative

• Increased manufacturing and personnel costs due to the pandemic.

ALLEN, Texas, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced that for the second quarter ended June 30, 2021, revenues totaled $42.7 million compared with $38.0 million for the same period in 2020. Net income for the second quarter of 2021 totaled $8.9 million as compared to $8.6 million for the same period in 2020, with diluted earnings per share for the second quarter of 2021 at $4.88 compared to $4.68 for the second quarter of 2020.

Commenting on results for the second quarter of 2021, David Battat, President and CEO, stated, “In our press release announcing first quarter 2021 results, we highlighted that after three consecutive pandemic quarterly declines in sales during 2020, we turned the corner in early 2021 and expected continued improvements as the year progressed. I am especially pleased that we met those expectations in the second quarter of this year with sequential increases of 9% in revenues, 10% in operating income and 16% in net income.” Mr. Battat continued, “When comparing our quarterly results to the second quarter of 2020, revenues were up 12% while other measurements were mixed, reflecting increased manufacturing and other personnel costs to support the safety and financial needs of our employees due to the continuing pandemic.”

Addressing the outlook for the remainder of 2021, Mr. Battat added, “Barring major disruptions due to COVID-19, we expect the remaining quarters of the year to show increases in sales and operating income of approximately 25% compared to the same quarters in 2020. Consistent with our prior practices, we will return capital to our stockholders through increasing dividends and opportunistic purchases of our stock. Cash and short and long term investments totaled $80.0 million as of June 30, 2021, following the purchases of 17,123 shares of our common stock in the second quarter at an average price of $613 per share, for a total cost of $10.5 million.”

Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com.

Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially. Such statements include, but are not limited to, Atrion's expectations regarding results for the remaining quarters of 2021 and return of capital through increasing dividends and stock repurchases. Words such as "expects," "believes," "anticipates," "forecasts," "intends," "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: the risk that the COVID-19 pandemic continues to lead to material delays and cancellations of, or reduced demand for, procedures in which our products are utilized; curtailed or delayed capital spending by hospitals and other healthcare providers; disruption to our supply chain; closures of our facilities; delays in training; delays in gathering clinical evidence; diversion of management and other resources to respond to the COVID-19 outbreak; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 virus continues to disrupt local economies and to cause economies in our key markets to enter prolonged recessions; changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition. The foregoing list of factors is not exclusive, and other factors are set forth in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date hereof, and we do not undertake any obligation, and disclaim any duty, to supplement, update or revise such statements, whether as a result of subsequent events, changed expectations or otherwise, except as required by applicable law.

Contact:	Jeffery Strickland
	Vice President and Chief Financial Officer
	(972) 390-9800

ATRION CORPORATION
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data)

	Three Months Ended June 30,								Six Months Ended June 30,
		2021				2020				2021				2020
Revenues	$	42,693			$	37,968			$	81,862			$	81,563
Cost of goods sold		24,826				20,499				47,656				44,226
Gross profit		17,867				17,469				34,206				37,337
Operating expenses		8,072				7,423				15,480				15,577
Operating income		9,795				10,046				18,726				21,760
Interest and dividend income		183				367				399				858
Other investment income (loss)		963				354				1,025				(673	)
Other income		--				--				66				--
Income before income taxes		10,941				10,767				20,216				21,945
Income tax provision		(2,017	)			(2,162	)			(3,565	)			(4,443	)
Net income	$	8,924			$	8,605			$	16,651			$	17,502
Income per basic share	$	4.89			$	4.69			$	9.12			$	9.49
Weighted average basic shares outstanding		1,826				1,835				1,826				1,844
Income per diluted share	$	4.88			$	4.68			$	9.10			$	9.47
Weighted average diluted shares outstanding		1,828				1,839				1,830				1,849

ATRION CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands)

	June 30,				Dec. 31,
ASSETS		2021				2020
	(Unaudited)
Current assets:
Cash and cash equivalents	$	17,070			$	22,450
Short-term investments		30,478				19,258
Total cash and short-term investments		47,548				41,708
Accounts receivable		22,682				16,445
Inventories		47,725				50,298
Prepaid expenses and other		7,873				3,868
Total current assets		125,828				112,319
Long-term investments		32,441				46,207
Property, plant and equipment, net		96,012				94,935
Other assets		13,357				13,429
	$	267,638			$	266,890
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities		12,699				13,636
Line of credit		--				--
Other non-current liabilities		14,248				12,812
Stockholders’ equity		240,721				240,442
	$	267,638			$	266,890

FAQ

What were Atrion Corporation's Q2 2021 revenues?

Atrion Corporation reported Q2 2021 revenues of $42.7 million.

How much net income did Atrion report for Q2 2021?

Atrion reported a net income of $8.9 million for Q2 2021.

What is the diluted earnings per share for Atrion in Q2 2021?

The diluted earnings per share for Q2 2021 is $4.88.

What are Atrion's growth projections for the remainder of 2021?

Atrion expects approximately a 25% increase in sales and operating income for the rest of 2021.

How much cash and investments did Atrion have as of June 30, 2021?

Atrion had $80 million in cash and short and long-term investments as of June 30, 2021.